index,id,research_title,initiation_date,status,has_result,locations,organization
0,NCT05003466,"A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years",2021-09,UNKNOWN,0,China,"Shenzhen Kangtai Biological Products Co., LTD"
1,NCT05089565,"Assessment of the Immune Response to SARS-CoV-2/COVID-19 Vaccination in Patients With Sarcoidosis",2021-12-01,COMPLETED,0,"United States","Northwestern University"
2,NCT04952766,"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults",2021-03-26,COMPLETED,0,France,"Centre Hospitalier Régional d'Orléans"
3,NCT05160766,"A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)",2021-11-08,COMPLETED,0,"Ireland,Norway,Germany,Spain,Lithuania","University of Cologne"
4,NCT04750720,"Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection According to the Clinical Severity of the Infection.",2020-08-27,COMPLETED,0,France,"Centre Hospitalier Régional d'Orléans"
5,NCT05125874,"A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines",2021-09-30,UNKNOWN,0,China,"Livzon Pharmaceutical Group Inc."
6,NCT04383574,"A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above",2020-05-22,COMPLETED,0,China,"Sinovac Biotech Co., Ltd"
7,NCT06035926,"Survey of Symptoms After a COVID Vaccination in Employees: a Retrospective Study.",2021-01-01,COMPLETED,0,Austria,"Medical University of Graz"
8,NCT05233826,"Phase 1 Study Evaluating the Safety and Immunogenicity of COVI-VAC as a Booster Dose in Previously Vaccinated Adults Against COVID-19",2022-04-14,COMPLETED,0,"United Kingdom","Codagenix, Inc"
9,NCT04548557,"Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial",2020-09-15,UNKNOWN,0,Pakistan,"University of Health Sciences Lahore"
10,NCT04834726,"Pragmatic Trial of COVID Vaccine Text Outreach Interventions",2021-04-29,COMPLETED,1,"United States","University of Pennsylvania"
11,NCT05313074,"SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients",2021-03-23,COMPLETED,0,Thailand,"National Cancer Institute, Thailand"
12,NCT05030974,"Optimal Repeated Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium",2021-10-21,COMPLETED,0,Netherlands,"University Medical Center Groningen"
13,NCT05534048,"A Phase III Study to Evaluate the Safety and Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination in Previously Vaccinated Adults Aged 18 Years and Older",2023-02-03,NOTYETRECRUITING,0,"","Everest Medicines (Singapore) Pte. Ltd."
14,NCT05445531,"Low-field Magnetic Resonance Imaging to Assess Changes in Pulmonary Function Parameters in Confirmed Pediatric SARS-CoV-2 Infection",2022-07-08,RECRUITING,0,Germany,"University of Erlangen-Nürnberg Medical School"
15,NCT05057182,"mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the ""mBoost"" Study)",2021-10-18,ACTIVENOTRECRUITING,0,"Hong Kong","The University of Hong Kong"
16,NCT04880174,"SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination",2021-03-22,ACTIVENOTRECRUITING,0,Belgium,"Universitair Ziekenhuis Brussel"
17,NCT04918940,"Post-vaccination Immunization Against SARS-CoV-2 in Patients Undergoing Maintenance With Anti-CD20 Antibodies for Follicular Lymphoma (FL) or Mantle Cell",2021-05-21,COMPLETED,0,France,"Centre Henri Becquerel"
18,NCT05142540,"Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines - The CoVVacBoost Study",2021-12-01,TERMINATED,0,Austria,"Medical University of Graz"
19,NCT04792567,"An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod)",2021-04-19,COMPLETED,1,Germany,Novartis
20,NCT04891172,"Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients",2021-08-01,RECRUITING,0,Pakistan,"Dow University of Health Sciences"
21,NCT04760704,"Evaluation of the Immunogenicity of mRNA BNT162b2 (COMIRNATY®) Vaccine in Elderly Subjects by Monitoring the Specific Cellular and Humoral Response.",2021-02-19,UNKNOWN,0,France,"University Hospital, Lille"
22,NCT04853004,"Studies of Ongoing and Completed SARS-CoV-2 Infection (Which Causes COVID-19) Within the Healthcare in Stockholm County, With Regard to Vaccinations.",2021-04-01,ACTIVENOTRECRUITING,0,Sweden,"Karolinska Institutet"
23,NCT05311904,"Observatory of the Efficacy and Safety of Vaccination Against SARS-CoV-2 in Neuromuscular Patients",2021-03-11,COMPLETED,0,France,"University Hospital, Bordeaux"
24,NCT04839146,"First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naïve Adult Volunteers in Good Health",2021-03-11,COMPLETED,1,Netherlands,"Radboud University Medical Center"
25,NCT06113692,"Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA- 1273 (ELASOMERAN)",2023-03-31,ACTIVENOTRECRUITING,0,"Spain,United Kingdom,Denmark,Norway","ModernaTX, Inc."
26,NCT06181292,"Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to Assess the Safety and Immunogenicity of a Booster Vaccination With an Adapted Recombinant Protein RBD Fusion Homodimer Candidate Against SARS-CoV-2, in Adults Vaccinated Against COVID-19",2023-11-15,ACTIVENOTRECRUITING,0,Spain,"Hipra Scientific, S.L.U"
27,NCT04566276,"A Phase 1/2, Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of the ChulaCov19 Vaccine in Healthy Adults",2021-05-03,COMPLETED,0,Thailand,"Chulalongkorn University"
28,NCT04894227,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac） in Health Adults Aged 26-45 Years",2021-05-11,COMPLETED,0,China,"Sinovac Biotech Co., Ltd"
29,NCT04436276,"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older",2020-07-15,COMPLETED,1,"United States,Belgium","Janssen Vaccines & Prevention B.V."
30,NCT04993560,"Comparing the Safety and Efficacy of Homologous and Heterologous COVID-19 Prime-boost Vaccination in Bahrain",2021-07-18,COMPLETED,0,Bahrain,"Royal College of Surgeons in Ireland - Medical University of Bahrain"
31,NCT04854876,"An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection",2021-08-15,WITHDRAWN,0,"","Royal College of Surgeons in Ireland - Medical University of Bahrain"
32,NCT05076227,"Comparison of Different BNT162b2 and ChAdOx1-S COVID-19 Vaccination Intervals and Combinations on Reactogenicity and Humoral Immunogenicity in Adults",2021-01-30,COMPLETED,0,Germany,"University of Witten/Herdecke"
33,NCT05077176,"Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",2021-10-08,COMPLETED,0,Turkey,"Health Institutes of Turkey"
34,NCT05032976,"A Prospective, Single-arm, Open-label, Non-interventional, Multicenter to Assess the Safety of BNT162b2 in Domestic Post-marketing Surveillance",2022-03-18,ACTIVENOTRECRUITING,0,"Korea, Republic of",Pfizer
35,NCT05305573,"A Phase IIb, Double-Blind, Randomized, Active Controlled, Multi-center, Non-inferiority Trial to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19",2022-03-25,COMPLETED,0,Spain,"Hipra Scientific, S.L.U"
36,NCT04961229,"Booster Dose of mRNA SARS-CoV-2 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response With or Without Immunosuppression Reduction - Protocol for a Randomised Controlled Trial (BECAME Study)",2021-10,UNKNOWN,0,"","Rabin Medical Center"
37,NCT04768244,"Impact of Maternal SARS-CoV-2 Infection and Vaccination on Breast Milk Antibodies, Milk Bioactive Compounds and Maternal-child Health (MilkCORONA)",2020-04-01,COMPLETED,0,Spain,"Institute of Agrochemistry and Food Technology, National Research Council"
38,NCT05153044,"Severe Acute Respiratory Syndrome CoV 2 Seroprevalence Survey and Vaccination Coverage in the Sickle Cell Population in Ile-De-France",2021-12-30,UNKNOWN,0,"","Assistance Publique - Hôpitaux de Paris"
39,NCT04922944,"Post Vaccination Antibody Assays and Reactions in Hospital Employees and Medical Staff: An Analysis of Antibody Response Over Time",2021-03-08,COMPLETED,0,"United States","Huntington Memorial Hospital"
40,NCT04848467,"COVID-19: A Phase 3, Randomized, Observer-blinded, Multicenter Clinical Study Evaluating the Immunogenicity, Safety, and Reactogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV, When Co-administered With a Licensed Quadrivalent Influenza Vaccine Versus Separate Administration of the Two Vaccines in Adults 60 Years of Age and Older",2021-10-01,WITHDRAWN,0,"",Bayer
41,NCT04414267,"A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial",2020-05-26,COMPLETED,0,Greece,"Hellenic Institute for the Study of Sepsis"
42,NCT05552573,"A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above",2022-07-19,ACTIVENOTRECRUITING,0,China,"Guangzhou Patronus Biotech Co., Ltd."
43,NCT04894682,"Safety and Long-term Effects of COVID-19 Vaccines in Patients With Lung Cancer or Indeterminate Pulmonary Nodule--A Real World Study",2021-05-04,WITHDRAWN,0,China,"Guangdong Provincial People's Hospital"
44,NCT06429020,"Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy: A Retrospective Study",2023-01-01,COMPLETED,0,Taiwan,"Chimei Medical Center"
45,NCT04852276,"Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations",2021-04-20,COMPLETED,0,"United States","National Institutes of Health Clinical Center (CC)"
46,NCT05435027,"A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912, GRT-R914, and GRT-R918 Administered as Prime and/or Boost in Healthy Adult Participants and People Living With HIV",2022-02-28,COMPLETED,0,"South Africa","Gritstone bio, Inc."
47,NCT06452082,"Retrospective Observational Study on the Risk in Developing Long-COVID Syndrome After Acute COVID-19 Disease and in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Supplementation in Outpatients of Endocrinology Department",2024-03-20,ACTIVENOTRECRUITING,0,Italy,"IRCCS San Raffaele"
48,NCT04537130,"Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)",2020-12-01,UNKNOWN,0,Spain,"Instituto Oncológico Dr Rosell"
49,NCT05925127,"A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults ≥ 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines",2023-10-16,ACTIVENOTRECRUITING,0,"United States",Novavax
50,NCT05633927,"Prospective Study to Evaluate the Persistence and Characteristics of Humoral and Cellular Immunity Against SARS-COV-2 After Vaccination in HIV-infected Patients Severely Immunosuppressed",2021-04-01,ACTIVENOTRECRUITING,0,Spain,"Hospitales Universitarios Virgen del Rocío"
51,NCT05079165,"EVALUATION OF THE RESPONSE TO mRNA SARS-CoV-2 VACCINE IN A COHORT OF LIVER TRANSPLANTED OR LISTED PATIENTS",2021-06-01,UNKNOWN,0,France,"University Hospital, Strasbourg, France"
52,NCT05050474,"A Clinical Study to Evaluate the Immunogenicity and Safety of the Third Dose Booster Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants",2021-08-07,COMPLETED,0,China,"Livzon Pharmaceutical Group Inc."
53,NCT05293665,"A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine",2022-03-16,ACTIVENOTRECRUITING,0,"Panama,United States,Philippines","Vaxxinity, Inc."
54,NCT04347694,"COVID-19 Serology in Nephrology Health Care Workers",2020-04-11,UNKNOWN,0,Austria,"Medical University of Vienna"
55,NCT05401825,"Antenatal COVID 19 VACCINATION and Pregnancy Outcomes",2022-02-18,RECRUITING,0,Egypt,"Ain Shams University"
56,NCT04754594,"A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER",2021-02-16,COMPLETED,0,"Brazil,South Africa,United Kingdom,Spain,United States","BioNTech SE"
57,NCT06175494,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) for the Prevention of SARS-CoV-2 Infection in a Population of 18 Years of Age and Older.",2023-12-19,RECRUITING,0,China,"WestVac Biopharma Co., Ltd."
58,NCT05950776,"A Multi-center, Randomized Placebo-controlled Phase II Trial to Assess the Safety, Tolerability and Immunogenicity of Two Doses of the Candidate Vaccine MVA-SARS-2-S in Adults Aged 18 to 64 and 65 and Older",2021-01-15,WITHDRAWN,0,"","Universitätsklinikum Hamburg-Eppendorf"
59,NCT05011344,"Evolution of Protective Immunization Against SARS-CoV-2 Among Hospital Workers in Health Care Facilities",2020-07-15,UNKNOWN,0,France,"Assistance Publique Hopitaux De Marseille"
60,NCT04794829,"Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination",2021-08-19,RECRUITING,0,"United States","National Institutes of Health Clinical Center (CC)"
61,NCT05729191,"Evaluation of the Acceptance of the Anti-COVID-19 Vaccine Offer and of the Knowledge and Attitudes Towards the Vaccination Among Pregnant Women Through a Validation Study at the Fondazione Policlinico Universitario A IRCCS Twins (FPG).",2021-10-25,COMPLETED,0,Italy,"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"
62,NCT05060991,"Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT)",2021-09-24,UNKNOWN,0,"United States","University of California, Davis"
63,NCT05433194,"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (Omicron) mRNA Vaccine (ABO1009-DP) for Sequential Immunization in the Population Aged 18 Years and Older Who Have Completed the Full Vaccination",2022-08-22,ACTIVENOTRECRUITING,0,"United Arab Emirates","Suzhou Abogen Biosciences Co., Ltd."
64,NCT05315362,"Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery by Solid Micro Needle Skin Patch of mRNA SARS-CoV-2 Vaccine as a Revaccination Strategy in Healthy Volunteers",2022-05-01,UNKNOWN,0,Netherlands,"Leiden University Medical Center"
65,NCT04924894,"Determinants of Obtaining COVID-19 Vaccination Among Health Care Workers Accessible to Free COVID-19 Vaccination: a Cross Sectional Study",2021-06-10,UNKNOWN,0,"","Assiut University"
66,NCT04954469,"B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency",2021-06-30,COMPLETED,0,Germany,"University Hospital Tuebingen"
67,NCT05074368,"Comparative Analysis of Neutralizing Antibody Response Among Heterologous ChAdOx1-nCov-19/mRNA-1273 Vaccination and Homologous ChAdOx1-nCov-19 or Homologous mRNA-1273 Vaccination",2021-07-06,COMPLETED,0,Taiwan,"National Taiwan University Hospital"
68,NCT04844489,"Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People",2021-04-16,COMPLETED,0,France,"Assistance Publique - Hôpitaux de Paris"
69,NCT04869072,"A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy",2020-04-29,COMPLETED,0,Switzerland,"University of Zurich"
70,NCT04900467,"Multicenter, Randomized, Open-label Trial Comparing the Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine: Non-inferiority Trial",2021-05-28,UNKNOWN,0,France,"Assistance Publique - Hôpitaux de Paris"
71,NCT05489367,"Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?",2022-02-01,COMPLETED,0,Turkey,"Gaziosmanpasa Research and Education Hospital"
72,NCT04582344,"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated",2020-09-14,COMPLETED,0,Turkey,"Health Institutes of Turkey"
73,NCT04785144,"Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults",2021-03-31,COMPLETED,1,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
74,NCT05977192,"Mobile Health-based Motivational Interviewing to Promote Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Oklahomans",2024-04-01,NOTYETRECRUITING,0,"United States","Oklahoma State University"
75,NCT04895189,"Yale COVID-19 Recovery Vaccine Study: Measuring Changes in Long Covid Symptoms After Vaccination",2021-05-03,ACTIVENOTRECRUITING,0,"United States","Yale University"
76,NCT05175989,"Real-world SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following BNT162b2 mRNA Vaccination Against COVID-19: a Prospective Cohort Study",2022-01-10,UNKNOWN,0,Israel,"Rabin Medical Center"
77,NCT04799392,"NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons",2021-04-01,TERMINATED,0,"United States","NOWDiagnostics, Inc."
78,NCT05204589,"Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults Aged 18 Years and Above: a Multicenter, Open-label, Partially Parallel-controlled Clinical Trial",2022-01-22,UNKNOWN,0,China,"Jiangsu Province Centers for Disease Control and Prevention"
79,NCT05022472,"Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California",2021-07-16,COMPLETED,0,"United States","University of California, San Diego"
80,NCT06333704,"A Multi-Centre, Prospective, Observational Post-Marketing Surveillance to Investigate the Long-Term Safety of SPIKEVAX BIVALENT and SPIKEVAX X Injection Under Routine Clinical Care in Korea",2023-03-10,RECRUITING,0,"Korea, Republic of","ModernaTX, Inc."
81,NCT04833101,"Safety and Immunogenicity of a Heterologous Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Against COVID-19 in Chinese Healthy Population",2021-04-07,COMPLETED,0,China,"Jiangsu Province Centers for Disease Control and Prevention"
82,NCT06360744,"A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines (ENFORCE PLUS)",2021-07-05,COMPLETED,0,Denmark,"Rigshospitalet, Denmark"
83,NCT05222139,"""Multicenter Observational Study to Assess the Incidence and Features of COVID-19 and the Response to COVID-19 Vaccination in Fragile Patients""",2021-05-24,UNKNOWN,0,"Ireland,Argentina,Gabon,Netherlands,India,Italy,Luxembourg,Spain","University of Bologna"
84,NCT04642339,"Randomized, Double-blind, Placebo Controlled, Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection",2020-11,UNKNOWN,0,"","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
85,NCT04659239,"A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above",2021-01-28,UNKNOWN,0,"Malaysia,Brazil",ChineseAMS
86,NCT05827939,"Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups",2022-06-01,RECRUITING,0,Taiwan,"Chang Gung Memorial Hospital"
87,NCT04761822,"Systemic Allergic Reactions to SARS-CoV-2 Vaccination",2021-04-07,COMPLETED,1,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
88,NCT04505722,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older",2020-09-07,COMPLETED,1,"Argentina,Chile,Peru,Brazil,South Africa,Mexico,Colombia,United States","Janssen Vaccines & Prevention B.V."
89,NCT04878822,"Prospective, Cohort, Non-interventional, Single-center Clinical Study of Immune Response Status to SARS-CoV-2 / Covid-19 Vaccination in Patients With Haematological Malignancies.",2021-04-13,UNKNOWN,0,Italy,"Ospedale di Circolo - Fondazione Macchi"
90,NCT05083039,"Observational Program to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers Aged 18-65",2020-05-14,COMPLETED,0,"Russian Federation","Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"
91,NCT05197673,"Identifying Risks of Outbreaks in Work Settings and the Implications for Control Measures",2022-03-15,COMPLETED,0,"Hong Kong","Chinese University of Hong Kong"
92,NCT05787431,"Levels of Physical Activity After SARS-CoV-2 Infection in Greek Adults: the Role of Pre-illness Vaccination and the Number of Reinfections.",2023-02-07,RECRUITING,0,Greece,"National and Kapodistrian University of Athens"
93,NCT04907331,"Comparison of Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost to Homolog Vaccination",2021-05-10,UNKNOWN,0,Austria,"Medical University Innsbruck"
94,NCT05164731,"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above After a Two-dose Schedule",2021-12-16,UNKNOWN,0,China,ChineseAMS
95,NCT05157230,"Evaluation of Deltoid Muscle Exercises on Injection Site and Arm Pain After Pfizer - BioNTech (BNT162b2) COVID - 19 Vaccination, A Randomized Controlled Study",2021-09-01,COMPLETED,0,Turkey,"Bursa Yüksek İhtisas Education and Research Hospital"
96,NCT05145348,"Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome",2021-02-03,UNKNOWN,0,Netherlands,"UMC Utrecht"
97,NCT04614948,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older",2020-11-12,COMPLETED,0,"Philippines,Brazil,Germany,South Africa,United Kingdom,Colombia,France,United States,Belgium,Spain","Janssen Vaccines & Prevention B.V."
98,NCT05244330,"Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2) in China-A Real World Study",2021-12-15,COMPLETED,0,China,"First Affiliated Hospital Xi'an Jiaotong University"
99,NCT04747522,"SARS-CoV-2 Cellular and Humoral Immune Response Following Vaccination of Kidney Transplant Recipients and Healthy Controls",2021-01-22,ACTIVENOTRECRUITING,0,Norway,"Oslo University Hospital"
100,NCT05055531,"""Effects of the Vaccin Against COVID 19 in a Cohort of Dialysis Patients: Adverse Events and Immunological Response""",2021-08-08,UNKNOWN,0,France,"Raincy Montfermeil Hospital Group"
101,NCT05764174,"Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance",2022-09-21,COMPLETED,0,"United States","Johns Hopkins Bloomberg School of Public Health"
102,NCT05873374,"A Phase 2 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of Baiya SARS-CoV-2 Vax 2 Vaccine as a Booster Following Vaccination for COVID-19 in Adults Between 18 and 64 Years",2023-12,NOTYETRECRUITING,0,Thailand,"Baiya Phytopharm Co., Ltd."
103,NCT05046548,"Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years",2020-10-03,COMPLETED,0,"Russian Federation","Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"
104,NCT05939648,"Randomized, Blinded, Positive and Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Booster Vaccination in People 18 Years of Age and Older Who Have Received SARS-CoV-2 Vaccine.",2023-10-09,ACTIVENOTRECRUITING,0,China,"AIM Vaccine Co., Ltd."
105,NCT05116748,"Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients",2021-10-01,COMPLETED,0,Italy,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"
106,NCT05618548,"Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium: a Non-commercial Multicenter Academic Prospective Cohort Study in Pregnant and Lactating Women",2021-03-01,ACTIVENOTRECRUITING,0,Belgium,"Universiteit Antwerpen"
107,NCT04864548,"A Dose Finding Human Experimental Infection Study With SARS-CoV-2 in Healthy Volunteers With Immunologically Sensitised With Either Previous, SARS-CoV-2 Infection and/or Vaccination Against SARS-CoV2",2021-05-27,RECRUITING,0,"United Kingdom","University of Oxford"
108,NCT05212948,"A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Cross-over Study to Evaluate the Efficacy, Safety, and Immunogenicity of S-268019 for the Prevention of COVID-19",2021-12-25,COMPLETED,0,Vietnam,"Shionogi Inc."
109,NCT05009030,"Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer",2021-05-06,COMPLETED,0,Spain,"Fundación GECP"
110,NCT05198063,"To Evaluate the Immunogenicity and Safety of Booster Immunization 6 Months After the Completion of Basic Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cell) in People 18 Years Old and Above",2022-01-10,COMPLETED,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
111,NCT04969263,"Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses",2021-08-10,COMPLETED,1,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
112,NCT04852822,"Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL",2021-03-18,ACTIVENOTRECRUITING,0,"United States","University of Washington"
113,NCT04880122,"Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 2 Antibodies in a Population of Nursing Home Residents.",2020-08-01,COMPLETED,0,Belgium,"University Ghent"
114,NCT04993586,"A Randomized, Open-label, Uncontrolled, Phase I/II Study to Assess Safety and Immunogenicity of Two or Three Dosing of Intramuscular/Intradermal AG0302-COVID19",2021-07-29,COMPLETED,0,Japan,"AnGes, Inc."
115,NCT04346186,"COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff",2020-04-15,COMPLETED,0,Denmark,"Herlev Hospital"
116,NCT05534035,"A Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated With Vaxzevria®",2023-02-03,NOTYETRECRUITING,0,"","Everest Medicines (Singapore) Pte. Ltd."
117,NCT04894435,"Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is ""Mix and Match"" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?",2021-05-20,ACTIVENOTRECRUITING,0,Canada,"Canadian Immunization Research Network"
118,NCT05477186,"A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old",2022-08-12,COMPLETED,0,"United States,Philippines,Australia",GlaxoSmithKline
119,NCT05082935,"Optimizing SARS-CoV-2 Testing and Promotores Interventions to Serve Latinx Communities",2021-09-15,COMPLETED,0,"United States","University of Oregon"
120,NCT04646239,"Determining Biomarkers of Trained Immunity in a Randomized Controlled Trial of the Measles, Mumps, and Rubella Vaccine - a Sub-study of the CROWN CORONATION Trial",2020-12-17,COMPLETED,0,"United States","Washington University School of Medicine"
121,NCT05000216,"Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)",2021-08-13,COMPLETED,0,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
122,NCT04932824,"A Long-term Follow-up Study to the Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of SCB-2019, a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19",2021-01-19,COMPLETED,0,Australia,"Clover Biopharmaceuticals AUS Pty Ltd"
123,NCT04417335,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial",2020-04-16,UNKNOWN,0,Netherlands,"Radboud University Medical Center"
124,NCT04877496,"Registry Study for COVID19 Vaccination Efficacy in Patients With a Treatment History of Rituximab.",2021-04-26,UNKNOWN,0,Switzerland,"Insel Gruppe AG, University Hospital Bern"
125,NCT04564716,"Сlinical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-СoV-2 Infection Prophylactic Treatment in Republic of Belarus",2020-09-28,UNKNOWN,0,Belarus,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
126,NCT04530396,"Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-СoV-2 Infection Prophylactic Treatment",2020-09-07,UNKNOWN,0,"Russian Federation","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
127,NCT05587868,"Karakteristik Dan Pengaruh Vaksinasi COVID-19 Terhadap Klinis Dan Kualitas Hidup Pasien Long COVID di RSUPN Dr. Cipto Mangunkusumo",2022-03-11,RECRUITING,0,Indonesia,"Indonesia University"
128,NCT05715944,"Open-Label, Single-Arm, Phase 3b Study of the Incidence of Severe COVID-19 and Adverse Events Following AZD1222 COVID-19 Vaccination in Botswana Against SARS-CoV-2, AZD1222 - ESR-21-21311",2021-09-15,COMPLETED,0,Botswana,"Botswana Harvard AIDS Institute Partnership"
129,NCT04962308,"An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.",2021-06-19,UNKNOWN,0,China,"Sinovac Biotech Co., Ltd"
130,NCT05031468,"Observational, Prospective Cohort Study of the Immunogenicity and Safety of SARS-CoV-2 Vaccines Administered During Pregnancy or Postpartum and Evaluation of Antibody Transfer and Durability in Infants",2021-07-06,COMPLETED,0,"United States","Emory University"
131,NCT06130410,"COMIRNATY Intramuscular Injection for 6 Months to 4 Years Old (Monovalent: Omicron XBB.1.5) Special Investigation for Booster Immunization in Children Aged 6 Months to 4 Years",2024-03-06,ACTIVENOTRECRUITING,0,Japan,Pfizer
132,NCT05023512,"Together Researching Understanding, Solidarity, and Trust Around COVID - TRUST Study",2021-10-28,WITHDRAWN,0,"","University of Massachusetts, Worcester"
133,NCT04834401,"Evaluating the Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in People With Multiple Sclerosis",2021-03-22,COMPLETED,0,"United States","St. Barnabas Medical Center"
134,NCT04380701,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",2020-04-23,UNKNOWN,0,Germany,"BioNTech SE"
135,NCT05087368,"An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.",2021-12-01,UNKNOWN,0,Brazil,"D'Or Institute for Research and Education"
136,NCT05043168,"Kidney Histopathological Features in Patients After COVID-19 and SARS-CoV-2 Vaccination",2021-09-18,COMPLETED,0,Germany,"University of Giessen"
137,NCT04468958,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects",2020-07-01,COMPLETED,0,"United States","SAb Biotherapeutics, Inc."
138,NCT05602558,"A Randomized, Double-blinded, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine",2022-12,NOTYETRECRUITING,0,"","Yantai Patronus Biotech Co., Ltd."
139,NCT04869358,"Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS)",2021-05-27,COMPLETED,0,Germany,Novartis
140,NCT04665258,"Corona Virus Disease 19 (COVID-19) Vaccine and Impact on Fertility Study",2020-12-14,WITHDRAWN,0,"","University of Miami"
141,NCT05268458,"Myocarditis After SARS-CoV2-Vaccination: An International Patient Registry on Clinical Manifestations and Outcomes",2021-11-12,UNKNOWN,0,Germany,"Theresien Hospital Mannheim"
142,NCT05960058,"Acceptance and Effectiveness of SARS-COV-2 Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation",2023-07,NOTYETRECRUITING,0,"","Assistance Publique - Hôpitaux de Paris"
143,NCT05249816,"An Observer-Blinded Phase 3 Study to Evaluate the Safety and Immunogenicity of a Single Booster of the NVX-CoV2373 Vaccine in Adults Previously Vaccinated With the BBIBP-CorV Vaccine",2022-03-18,COMPLETED,0,"United Arab Emirates","Cogna Technology Solutions LLC"
144,NCT05021016,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",2020-11-19,COMPLETED,0,"Russian Federation","Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector"""
145,NCT05501522,"A Phase III, Placebo-controlled, Randomized, Observer-blinded, Multi-national, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older",2022-12-09,ACTIVENOTRECRUITING,0,"Nepal,Colombia","SK Bioscience Co., Ltd."
146,NCT05894525,"Cohort Survey on Acute Phase Safety in Persons With Underlying Diseases Considered to Be at High Risk of Severe COVID-19 by Using Vaccination Information",2022-11-15,COMPLETED,0,Japan,"ModernaTX, Inc."
147,NCT05743335,"A PHASE 1/2 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BROADLY PROTECTIVE mRNA VACCINE JCXH-221 AGAINST SARS-CoV-2 INFECTION AND DISEASES",2023-03-20,RECRUITING,0,"United States","Immorna Biotherapeutics, Inc."
148,NCT04964024,"SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes",2021-07-15,COMPLETED,0,France,"Central Hospital, Nancy, France"
149,NCT05237024,"Monitoring of Physiologic Changes Associated With Immune System Activation Associated With Vaccination Against the SARS-CoV-2 Virus: Vaccine-Induced Inflammation Identification",2021-04-15,UNKNOWN,0,"United States,Canada","physIQ, Inc."
150,NCT04956224,"A Phase III, Open Label, Multicenter, Single Arm Study to Assess the Safety, Tolerability and Immunogenicity of VLA2001 in Volunteers Aged ≥ 56 Years.",2021-08-09,COMPLETED,0,"New Zealand","Valneva Austria GmbH"
151,NCT04362124,"Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medellín, Colombia, 2020",2020-08,WITHDRAWN,0,Colombia,"Universidad de Antioquia"
152,NCT04672395,"A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older",2021-03-24,COMPLETED,0,"Philippines,South Africa,Brazil,Colombia,Belgium","Clover Biopharmaceuticals AUS Pty Ltd"
153,NCT05028881,"Serological Responses to SARS-CoV-2 and Their Temporal Pattern in HIV Infected Persons",2020-05-16,ENROLLINGBYINVITATION,0,China,"Chinese University of Hong Kong"
154,NCT04944095,"Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities",2021-08-10,RECRUITING,0,"United States","Boston Biopharm, Inc."
155,NCT05004181,"A Phase II Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Monovalent and Multivalent RNA-based Vaccines in Healthy Subjects",2021-08-25,COMPLETED,0,"South Africa,United States,Germany,Turkey","BioNTech SE"
156,NCT04944381,"a Voluntary, Investigator-initiated, Inactivated COVID-19 Vaccine Controlled Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Above",2021-07-02,UNKNOWN,0,"",ChineseAMS
157,NCT06435403,"SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Health Care Worker and Community Members From Ethiopian Related to Natural SARS CoV-2 Infection and COVID-19 Vaccination",2022-11-10,RECRUITING,0,Ethiopia,"Ludwig-Maximilians - University of Munich"
158,NCT04715438,"Vaccination Against cOvid In CancEr",2021-01-08,ACTIVENOTRECRUITING,0,Netherlands,"University Medical Center Groningen"
159,NCT05387395,"Impact of COVID 19 Vaccination or Infection on Disease Activity in Radiologically Isolated Syndrome Cohort: the VaxiRIS Study",2022-05-31,COMPLETED,0,France,"Centre Hospitalier Universitaire de Nice"
160,NCT04560881,"Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years",2020-09-16,COMPLETED,0,Argentina,"Laboratorio Elea Phoenix S.A."
161,NCT05303402,"A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess the Immunogenicity and Safety of an Additional Dose Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19",2022-05-12,COMPLETED,0,"Spain,Turkey","Hipra Scientific, S.L.U"
162,NCT04475302,"Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India",2020-07-01,COMPLETED,0,India,"Tuberculosis Research Centre, India"
163,NCT04652102,"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older",2020-12-11,COMPLETED,1,"Argentina,Dominican Republic,Peru,Netherlands,Germany,Panama,Mexico,Colombia,Spain,Belgium",CureVac
164,NCT05046002,"COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry (COVID-VIHPR)",2021-08-11,RECRUITING,0,Canada,"Ottawa Heart Institute Research Corporation"
165,NCT04468802,"Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by SARS CoV-2 in OECD Countries?",2020-02-01,COMPLETED,0,Turkey,"Kanuni Sultan Suleyman Training and Research Hospital"
166,NCT04978038,"Fourth Dose of Pfizer mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities",2022-08-01,UNKNOWN,0,Canada,"McMaster University"
167,NCT04863638,"A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old",2021-04-29,ACTIVENOTRECRUITING,0,China,"China National Biotec Group Company Limited"
168,NCT04969250,"SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients",2021-08-25,COMPLETED,1,"Nigeria,Switzerland,Singapore,Spain,United States,Uganda","National Institute of Allergy and Infectious Diseases (NIAID)"
169,NCT05359250,"Evaluation of Myocardial Dysfunction Due to mRNA-based SARS-CoV-2 Vaccines",2021-05-12,RECRUITING,0,"United States","University of Colorado, Denver"
170,NCT05153850,"Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2 in Patients With Inflammatory Bowel Disease Under Inmunosuppressor Treatment",2022-01-01,UNKNOWN,0,Spain,"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla"
171,NCT05188469,"A Phase I/IIa (Multi-center, Open-label, Phase I and Multi-center, Open-label, Phase IIa ) Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers",2022-03-22,ACTIVENOTRECRUITING,0,Australia,"EyeGene Inc."
172,NCT04830046,"Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia",2021-09,UNKNOWN,0,"United States","Massachusetts General Hospital"
173,NCT05633446,"A Phase I-II, Double-blind, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults",2023-05-23,NOTYETRECRUITING,0,Philippines,"Emergex Vaccines Holding Ltd."
174,NCT05228912,"Analysis of Immunization Time, Amplitude and Adverse Events of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries",2021-02-26,COMPLETED,0,Mexico,"Hospital Clinica Nova"
175,NCT05234346,"An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection",2022-03-15,COMPLETED,0,India,"Vedic Lifesciences Pvt. Ltd."
176,NCT04702295,"COVID Vaccination in Rare and Complex Connective Tissue Diseases: ERN ReCONNET Multicentre Prospective Cohort Study",2021-02,UNKNOWN,0,"","University of Pisa"
177,NCT04939350,"Evaluation of the Vaccination Coverage in a Prospective Cohort of Cirrhotic Patients Followed in the General Hospitals in France in 2021 and in 2022.",2021-09-27,COMPLETED,0,France,"Centre Hospitalier Sud Francilien"
178,NCT05367895,"Effectiveness of CoronaVac® First Booster Dose for Preventing Symptomatic Acute Respiratory Infection Caused by SARS-CoV-2 Virus in Adults in São Paulo City, Brazil: a Retrospective Test-negative Case-control Study",2022-07-30,UNKNOWN,0,Brazil,"Sinovac Biotech Co., Ltd"
179,NCT05175950,"A Placebo-controlled, Randomized, Observer-blinded, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Booster Vaccination of A SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)",2022-01-24,ACTIVENOTRECRUITING,0,"Korea, Republic of","Korea University Guro Hospital"
180,NCT04905823,"Effect of SARSCoV2 Vaccination in Type 1 Diabetes (CoVaxT1D)",2021-03-31,COMPLETED,0,Italy,"University of Milan"
181,NCT04970550,"Vaccination Against SARS-Cov2 in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.",2021-06-01,COMPLETED,0,France,"Hopital Nord Franche-Comte"
182,NCT05855408,"Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults Aged 18 Years or Above: a Multicenter, Parallel Groups, Partially Randomized, Open-label, Blank-controlled Adaptive Platform Trial",2023-05-18,NOTYETRECRUITING,0,China,"Jiangsu Province Centers for Disease Control and Prevention"
183,NCT04412538,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",2020-05-15,COMPLETED,0,China,"Institute of Medical Biology, Chinese Academy of Medical Sciences"
184,NCT05124223,"Analysis of Cardiac Damage Post Infection With SARS-CoV-2 and Post Vaccination Against COVID-19",2020-01-01,COMPLETED,0,Germany,"German Heart Institute"
185,NCT04799808,"Investigation of the Immune Response Before and After COVID-19 Disease or SARS-CoV-2 Vaccination in Dialysis Patients, Solid Organ Recipients and Medical Staff",2021-01-15,RECRUITING,0,Germany,"Technische Universität Dresden"
186,NCT04822012,"Anti COVID-19 Antibodies in Spermatic Fluid and Follicular Fluid",2021-03-01,UNKNOWN,0,Israel,"Meir Medical Center"
187,NCT06025812,"A Randomized, Double-blind, Active-controlled Clinical Study Evaluating the Immunogenicity and Safety of Omicron BA.4/5-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Older With Different Immunization Programs",2023-09-20,NOTYETRECRUITING,0,"","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
188,NCT05213455,"Booster Effect of mRNA Vaccine After Complete Vaccination With Sinos: an Observational Study",2022-01-01,UNKNOWN,0,Pakistan,"Lahore General Hospital"
189,NCT05126550,"The Immunogenicity, Safety, and Effectiveness of the SARS-CoV-2 Vaccine (Vero Cell) Inactivated in Adult Population Aged 18 Years Old and Above in Indonesia",2021-11-13,ACTIVENOTRECRUITING,0,Indonesia,"PT. Kimia Farma (Persero) Tbk"
190,NCT04924855,"Estimation of Dynamics of Humoral Immunity in COVID-19 Vaccined Health Care Workers",2021-07,UNKNOWN,0,Tunisia,"General Administration of Military Health, Tunisia"
191,NCT05025514,"Pharmaco-epidemiological Study of COVID 19 Vaccines in Patients Undergoing Immunotherapy for Cancer. A Retrospective Open Cohort Study.",2021-10-19,UNKNOWN,0,France,"Centre Hospitalier Universitaire de Nīmes"
192,NCT05895110,"To Evaluate the Immunogenicity and Safety of Sequentially Enhanced Recombinant Novel Coronavirus Vaccine (CHO Cells) in Patients Aged 3-17 Years After Completion of Two Doses of Novel Coronavirus Inactivated Vaccine",2022-04-29,COMPLETED,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
193,NCT05367908,"Discoveries - Different Immunization Boosters for Covid-19: Effect on Response in Antibodies",2022-04-11,COMPLETED,0,"United States","ModernaTX, Inc."
194,NCT04930055,"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)",2021-06-30,TERMINATED,0,"United States","Indiana University"
195,NCT04384614,"Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study Multicentric Study",2020-05-15,WITHDRAWN,0,Tunisia,"Direction des Soins de Santé de Base"
196,NCT05184114,"Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance",2021-10-04,RECRUITING,0,"Hong Kong","The University of Hong Kong"
197,NCT05812014,"A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older Who Completed Primary/1 Booster Dose(s) of SARS-CoV-2 Vaccination",2023-03-25,RECRUITING,0,Pakistan,"AIM Vaccine Co., Ltd."
198,NCT04917523,"Immunogenicity Non-inferiority Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 Years Old vs Healthy Population Aged 18 Years Old and Above",2021-07-02,COMPLETED,0,"United Arab Emirates","China National Biotec Group Company Limited"
199,NCT06105346,"Prevalence Study of ENT-related Diseases in Conscripts at the Military Induction Board",2023-12-01,NOTYETRECRUITING,0,"","Medical University of Graz"
200,NCT04800146,"A Prospective Observational Study on the Immune-response to SARS-CoV-2 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study",2021-02-25,COMPLETED,0,Switzerland,"Oncology Institute of Southern Switzerland"
201,NCT04795414,"Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers",2021-01-14,UNKNOWN,0,China,"Ruijin Hospital"
202,NCT04939155,"Measuring the DNA Methylation Effects From COVID-19 Infection and COVID-vaccinations",2021-03-10,UNKNOWN,0,"United States",TruDiagnostic
203,NCT05205096,"Study on the Immunogenicity and Safety of Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Inoculation With Two Doses of Inactivated Vaccine (CoronaVac) in People Over 18 Years Old",2021-11-10,COMPLETED,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
204,NCT06199934,"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data",2024-02-07,ACTIVENOTRECRUITING,0,"United States",Pfizer
205,NCT06038617,"A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety of Simultaneous Vaccination With mRNA COVID-19 Vaccine and Other Vaccines in Young Children Aged 6 Months to <5 Years.",2023-10-30,RECRUITING,0,"United States","Duke University"
206,NCT06168019,"Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE) Study in India",2023-12-26,RECRUITING,0,"United States,India","Boston University"
207,NCT04881396,"Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine",2021-05-10,COMPLETED,0,France,"Hospices Civils de Lyon"
208,NCT05165719,"Validation of Specificity, Sensitivity, and Accuracy for an ELISpot-based In-vitro Diagnostic (IVD) Kit 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response",2021-07-07,COMPLETED,0,"Russian Federation","National Research Center for Hematology, Russia"
209,NCT04370119,"Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers",2020-04-27,ACTIVENOTRECRUITING,0,Germany,"University Medicine Greifswald"
210,NCT05465863,"Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Pediatric Kidney Transplant Recipients Compared to Dialysis Patients and Healthy Children",2021-09-01,COMPLETED,0,Turkey,"Istanbul University - Cerrahpasa (IUC)"
211,NCT04741386,"The Immune-response and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant - A Prospective, Controlled, Multicenter Cohort Study by the RECOVAC Consortium",2021-02-17,COMPLETED,0,Netherlands,"University Medical Center Groningen"
212,NCT06191341,"Consequences in ICU of Vaccination Status of Covid-19 Patients",2023-01-01,COMPLETED,0,France,"Centre Hospitalier Régional Metz-Thionville"
213,NCT05115617,"Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination (PLAN-V): Prospective Cohort Study",2021-06-03,RECRUITING,0,Canada,"Ottawa Hospital Research Institute"
214,NCT04546841,"P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults",2020-11-27,COMPLETED,0,Germany,"University Hospital Tuebingen"
215,NCT05341713,"Epileptic Seizure in Epilepsy Patients After First-dose Inactivated SARS-CoV-2 Vaccination: a Self-controlled Case Series Study",2022-01-01,COMPLETED,0,China,"Xijing Hospital"
216,NCT05903118,"A Phase I/II, Randomized, Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (RBMRNA-176) in Healthy Adults Aged 18 Years and Older",2022-01-08,COMPLETED,0,China,"Argorna Pharmaceuticals Co., LTD"
217,NCT05273541,"Beijing 302 Hospital",2022-02-11,UNKNOWN,0,China,"Beijing 302 Hospital"
218,NCT05079217,"A Randomized, Double-Blinded Clinical Trial to Evaluate Additional Dose of Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine in Healthy Individuals Previously Vaccinated With CoronaVac",2021-12-17,UNKNOWN,0,China,"Sinovac Biotech Co., Ltd"
219,NCT05473936,"A Community Health Worker Intervention to Identify and Decrease Barriers to Pre-Procedural COVID 19 Testing Among Los Angeles County Department of Health Safety-Net Patients",2022-10-11,RECRUITING,0,"United States","Charles Drew University of Medicine and Science"
220,NCT04379336,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial",2020-05-04,COMPLETED,0,"South Africa","TASK Applied Science"
221,NCT05839236,"COVID-19 Vaccination Detoxication in Low Density Lipoprotein Cholesterol",2023-05-01,ACTIVENOTRECRUITING,0,China,"Pachankis, Yang I., M.D."
222,NCT05069649,"Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2",2021-10-06,COMPLETED,0,"Russian Federation","Materia Medica Holding"
223,NCT04895449,"A Multi-center Phase Ib Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults",2021-07-16,COMPLETED,0,Germany,"Universitätsklinikum Hamburg-Eppendorf"
224,NCT05324319,"Single Blinded Randomized Controlled Trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or ChAdOx1-S (Viral Vector) for Third Vaccination in Kidney Transplant Recipients Without SARS-CoV-2 Spike Protein Antibodies Following Full Vaccination",2021-06-15,UNKNOWN,0,Austria,"Medical University of Vienna"
225,NCT04587219,"An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years",2020-10-22,UNKNOWN,0,"Russian Federation","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
226,NCT04779541,"National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units",2021-06-02,COMPLETED,0,France,"University Hospital, Angers"
227,NCT04871841,"Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan",2021-04-05,COMPLETED,0,Kazakhstan,"Karaganda Medical University"
228,NCT05009134,"Influences of Allergic Rhinitis and Allergen Immunotherapy on Human Antibody Responses to SARS-CoV-2 Vaccination",2021-06-04,UNKNOWN,0,China,"Huazhong University of Science and Technology"
229,NCT04939402,"SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following COVID-19 Vaccination Using an Adenoviral Vector",2021-05-05,RECRUITING,0,Belgium,"Universitair Ziekenhuis Brussel"
230,NCT05890521,"Multi-center Safety Observation of COVID19 Vaccine in a Large Population",2022-04-02,RECRUITING,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
231,NCT04885764,"Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University",2021-02-23,UNKNOWN,0,Egypt,"Ain Shams University"
232,NCT04706390,"Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination",2021-01-12,RECRUITING,0,Norway,"University of Bergen"
233,NCT05886790,"A Randomized, Open-Label, Parallel-controlled Clinical Study on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes Among People Aged 18 Years and Older",2023-05-30,RECRUITING,0,China,"Zhongnan Hospital"
234,NCT05894590,"Cohort Survey on Non-Acute Safety in Persons With Underlying Diseases Who Are Considered to Be at High Risk of Severe COVID-19 by Using Vaccination Information",2022-11-15,COMPLETED,0,Japan,"ModernaTX, Inc."
235,NCT05198102,"To Evaluate the Immunogenicity and Safety of Booster Immunization 12 Months After the Completion of Basic Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cell) in People 18 Years Old and Above",2021-12-29,COMPLETED,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
236,NCT05465902,"Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines",2023-07-07,ACTIVENOTRECRUITING,0,Mexico,"WestVac Biopharma Co., Ltd."
237,NCT04563702,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers VXA-CoV2-1.1-S Boost Substudy: Boost at 1 Year Post Initial Vaccination With an Adenoviral-Vector Based Vaccine VXA-CoV2-1.1-S Expressing a SARS-CoV-2 S Protein in a Subset of Subjects",2020-09-21,COMPLETED,0,"United States",Vaxart
238,NCT04514302,"Phase I, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Antiviral Efficacy of Three Different Single Doses of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) in Adult Patients With Mild COVID-19",2021-12-07,COMPLETED,0,Mexico,"Hospital San Jose Tec de Monterrey"
239,NCT05652543,"Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants S Trimer Protein Vaccine (SCTV01E) in a Vaccinated Population",2023-01-05,COMPLETED,0,China,"Sinocelltech Ltd."
240,NCT05562479,"Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study.",2021-12-12,COMPLETED,0,Colombia,Novafem
241,NCT06057064,"A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)",2023-09-29,COMPLETED,0,"Russian Federation",AstraZeneca
242,NCT04611802,"A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)",2020-12-27,COMPLETED,0,"United States,Mexico,Puerto Rico",Novavax
243,NCT04949490,"A Phase II, Open-label, Rollover Trial to Evaluate the Safety and Immunogenicity of One or Two Boosting Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 Trial Subjects, or Two Boosting Doses of Comirnaty in BNT162-04 Trial Subjects",2021-07-26,COMPLETED,0,Germany,"BioNTech SE"
244,NCT04760990,"An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.",2021-02-01,UNKNOWN,0,Switzerland,"University Hospital, Basel, Switzerland"
245,NCT04811664,"A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine",2021-03-24,COMPLETED,1,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
246,NCT04651790,"Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.",2020-11-27,COMPLETED,0,Chile,"Pontificia Universidad Catolica de Chile"
247,NCT05035238,"Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine (TURKOVAC Inactive) in Healthy Population of 18 and 64 Years of Age (Both Inclusive): a Randomized, Double-blind, Phase IIb Clinical Trial",2021-09-20,UNKNOWN,0,Turkey,"Health Institutes of Turkey"
248,NCT04842708,"Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis",2020-12-24,COMPLETED,0,Israel,"Scentech Medical Technologies Ltd"
249,NCT05075538,"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2",2021-12-01,TERMINATED,0,Belgium,"Jules Bordet Institute"
250,NCT04352608,"A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years",2020-04-16,COMPLETED,0,China,"Sinovac Biotech Co., Ltd"
251,NCT05268679,"Study of the Humoral and Cellular Response to Vaccines Against SARS-CoV-2 in Heart Transplant Recipients",2022-03-07,COMPLETED,0,France,"Assistance Publique - Hôpitaux de Paris"
252,NCT05293379,"Prospective, Multicenter Study Assessing a Screening Campaign for Cardiovascular Diseases Risk Factors During SARS-CoV-2 Epidemic",2021-07-01,COMPLETED,0,France,Elsan
253,NCT05216484,"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)",2022-02-18,UNKNOWN,0,China,ChineseAMS
254,NCT05210179,"Open-Label, Two Arms, Multi-Centered, Phase 2b Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination (TURKOVAC) Against SARS-CoV-2",2022-01-24,COMPLETED,0,Turkey,"Health Institutes of Turkey"
255,NCT05973084,"COVID-19 Transmission and Morbidity in Malawi",2023-01-17,RECRUITING,0,"United States,Malawi","Boston University"
256,NCT05303584,"Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Three-dose Priming With an Inactivated COVID-19 Vaccine in Adults Aged 18 Years and Above: a Randomized, Open-label, Parallel-controlled Clinical Trial",2022-04-23,UNKNOWN,0,China,"Jiangsu Province Centers for Disease Control and Prevention"
257,NCT04796584,"Efficacy of COVID 19 SARS-CoV-2 mRNA Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication (SARSmRNA_MS)",2022-07-11,TERMINATED,0,"United States","Providence Health & Services"
258,NCT04884750,"Community-based Design and Evaluation of A Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches",2022-12-12,RECRUITING,0,"United States","Northeastern University"
259,NCT05552950,"Randomized, Controlled, Double-Blind Proof of Concept Trial Assessing the Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 Infection in Healthy Volunteer Individuals",2022-05-01,RECRUITING,0,Estonia,"Chemi-Pharm AS"
260,NCT04951323,"Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)",2021-03-22,UNKNOWN,0,Belgium,"University of Liege"
261,NCT04405908,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.",2020-06-19,COMPLETED,0,Australia,"Clover Biopharmaceuticals AUS Pty Ltd"
262,NCT04860908,"DOES COVID-19 INFECTION AND/OR VACCINATION OF PREGNANT WOMEN AFFECT THE PANCREATIC BETA CELLS OF THE FETUS BECOMING A TRIGGER FOR FUTURE DEVELOPMENT OF CHILDHOOD TYPE 1 DIABETES",2021-04-26,UNKNOWN,0,Israel,"Maaynei Hayesha Medical Center"
263,NCT04469179,"A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19",2020-08-20,UNKNOWN,0,"United States","SAb Biotherapeutics, Inc."
264,NCT05537103,"Adolescents Seeking COVID Vaccination",2022-09-26,COMPLETED,0,"United States","National Institutes of Health Clinical Center (CC)"
265,NCT05682638,"A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and Older",2023-01-30,RECRUITING,0,Kenya,"AIM Vaccine Co., Ltd."
266,NCT05492643,"A Single Center, Open Label Clinical Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine",2022-08-13,RECRUITING,0,China,"Zhongnan Hospital"
267,NCT04824638,"A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine",2021-03-08,COMPLETED,0,France,"ANRS, Emerging Infectious Diseases"
268,NCT05012943,"A Randomized, Observer-Blind, Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults",2021-08-15,COMPLETED,0,Vietnam,"Vinbiocare Biotechnology Joint Stock Company"
269,NCT05128643,"Clinical Study on the Immunogenicity and Safety of the Recombinant Novel Coronavirus（COVID-19）Vaccine (CHO Cell) 0-1-6 Month and 0-1-4 Month Immunization Programs in People Aged 18 and Above",2021-09-17,UNKNOWN,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
270,NCT05244343,"Impact of Vaccination on Medical and Intensive Care Hospitalization of COVID-19 Patients",2022-01-25,COMPLETED,0,Tunisia,"Eshmoun Clinical Research Center"
271,NCT04924803,"Community Developed Technology-Based Messaging to Increase SARS-CoV-2 Vaccine Uptake Among People Who Inject Drugs",2022-06-21,RECRUITING,0,"United States","New York University"
272,NCT05408299,"Comparative Study of Patterns of Immune Response to COVID 19 Vaccination Between Immunocompetent and Immunocompromised Subjects",2022-06-20,UNKNOWN,0,Egypt,"National Research Centre, Egypt"
273,NCT05593042,"Phase 2, Randomized, Double-blind Study to Evaluate Immunogenicity Superiority of a Booster Dose With an Omicron or a Trivalent Vaccine Compared to CoronaVac, in Adults Immunized With Different Vaccine Schedules Against SARS-CoV-2 in Chile",2022-11-28,COMPLETED,0,Chile,"Pontificia Universidad Catolica de Chile"
274,NCT05894499,"Cohort Survey on Shock and Anaphylaxis in Persons With Underlying Diseases Considered to Be at High Risk of Severe COVID-19 by Using Vaccination Information",2022-11-15,COMPLETED,0,Japan,"ModernaTX, Inc."
275,NCT05074706,"Evaluation of the Immune Response to Sars-Covid-19 (Cov-2) Vaccines in Haematological Patients: Prospective Single Center Study",2021-06-09,COMPLETED,0,Italy,"University of Milano Bicocca"
276,NCT05059106,"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19",2021-06-01,UNKNOWN,0,Brazil,"Federal University of Espirito Santo"
277,NCT04723706,"Immunological Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients",2021-03-19,COMPLETED,0,"United States","Henry Ford Health System"
278,NCT04648800,"A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland",2020-07-07,UNKNOWN,0,Poland,"University of Rzeszow"
279,NCT04826770,"Blood Donations From Healthy Probands for the Study of the Adaptive Immune Response to COVID-19 Vaccination (AICOVI)",2021-01-06,ACTIVENOTRECRUITING,0,Germany,"University Medicine Greifswald"
280,NCT04348370,"Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses",2020-04-20,ACTIVENOTRECRUITING,0,"United States","Texas A&M University"
281,NCT04912700,"The Impact of Vaccination on Severity of Illness in COVID-19: A Multicenter Cohort Study",2021-06-01,COMPLETED,1,"United States","William Beaumont Hospitals"
282,NCT05484700,"SARS-CoV-2 Neutralizing Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Correlation With Immunity and Long-COVID-19 Symptoms",2021-12-30,ACTIVENOTRECRUITING,0,Thailand,"Mahidol University"
283,NCT05109559,"A Phase 1/2 Study to Evaluate the Safety Reactogenicity and Immunogenicity of Ad26.COV2.S Administered as a Heterologous Booster Vaccination in Adults 18 Years of Age and Older Following Single- or Two-Dose Vaccination With an Inactivated COVID-19 Vaccine",2021-12-20,RECRUITING,0,Thailand,"Mahidol University"
284,NCT04892459,"Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial",2021-05-25,COMPLETED,0,China,"Jiangsu Province Centers for Disease Control and Prevention"
285,NCT05218070,"Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of Severe Acute Respiratory Syndrome (SARS) - Coronavirus 2 (CoV-2) Infection (COVID-19)",2022-02-06,UNKNOWN,0,Egypt,"Eva Pharma"
286,NCT05115370,"Barriers and Facilitators of Flu, Pneumonia and SARS-CoV-2 (COVID-19) Vaccination in Adults With Inflammatory Conditions Treated With Immune-suppressing Drugs",2021-11-01,COMPLETED,0,"United Kingdom","University of Nottingham"
287,NCT04904549,"A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older as a Primary Series and Open-label Extension to Assess Immunogenicity, Safety, Efficacy of a Monovalent Booster Dose of SARS-CoV2 Adjuvanted Recombinant Protein Vaccine",2021-05-26,ACTIVENOTRECRUITING,0,"Nigeria,Japan,Honduras,Kenya,Sri Lanka,Ukraine,Nepal,India,Mexico,Colombia,United States,Ghana,Uganda",Sanofi
288,NCT04979949,"Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",2021-07-12,COMPLETED,0,Turkey,"Health Institutes of Turkey"
289,NCT05876377,"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data",2023-10-23,RECRUITING,0,"United States",Pfizer
290,NCT05142553,"A Phase IIb, Double-blind, Randomised, Active-controlled, Multi-centre, Non-inferiority Trial Followed by a Phase III, Single-arm, Open-label Trial, to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)SARS-CoV-2, in Adults Fully Vaccinated Against COVID-19 Followed by an Extension Period to Study a Fourth Dose Administration of PHH-1V.",2021-11-16,COMPLETED,0,Spain,"Hipra Scientific, S.L.U"
291,NCT04894253,"Study of the Immune Response to SARS-CoV-2 Vaccination in Patients With Systemic Lupus",2021-06-07,RECRUITING,0,France,"University Hospital, Strasbourg, France"
292,NCT05338177,"Pilot Trial on Immunosuppression Modulation in Kidney Transplant Recipients Without SARS-CoV-2 Spike Protein Antibodies Following Full Vaccination",2021-11-15,UNKNOWN,0,Austria,"Medical University of Vienna"
293,NCT05655351,"How Does Vaccination Against COVID-19 Affect Monocyte Production of Oxygenated Derivatives ?",2022-12-21,ACTIVENOTRECRUITING,0,France,"Centre Hospitalier Universitaire de Nīmes"
294,NCT06189053,"Long-term Outcomes of Myocarditis Following Administration of SPIKEVAX (COVID-19 Vaccine mRNA)",2022-04-30,ACTIVENOTRECRUITING,0,"United States","ModernaTX, Inc."
295,NCT04954651,"Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received European Union (EU) -Approved COVID-19 Vaccines",2021-07-07,COMPLETED,0,Greece,"University of Patras"
296,NCT05205083,"Study on the Immunogenicity and Safety of Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Inoculation With Two Doses of Inactivated Vaccine (BBIBP-CorV) in People Over 18 Years Old",2021-11-10,UNKNOWN,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
297,NCT05050461,"Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma",2021-09-20,UNKNOWN,0,"","Versailles Hospital"
298,NCT05534061,"Motivational Enhancement to Augment Contingency Management for SARS-CoV-2 Testing and Vaccination Utilization Among Syringe Exchange Clients",2022-08-08,COMPLETED,1,"United States","University of Oregon"
299,NCT05960097,"A Phase 2 Randomized, Active-controlled, Observer-blind Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults Who Previously Received a Complete Primary Vaccination Series With or Without Booster Dose(s)",2023-08-01,ACTIVENOTRECRUITING,0,"United States,Australia",GlaxoSmithKline
300,NCT04515147,"COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age",2020-09-21,COMPLETED,1,"Panama,Peru",CureVac
301,NCT05020145,"Coronavirus Disease 2019 (COVID-19) Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States",2021-08-25,COMPLETED,1,"United States",Pfizer
302,NCT05096845,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older",2021-08-25,ACTIVENOTRECRUITING,0,"Russian Federation,Philippines,Indonesia","Livzon Pharmaceutical Group Inc."
303,NCT05547451,"SARS Cov2 Vaccination in Adolescents From 12 to 18 With Juvenile Idiopathic Arthritis in Angers, Nantes and Rennes : Acceptance and Safety.",2024-06-09,RECRUITING,0,France,"Nantes University Hospital"
304,NCT04790851,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",2021-03-10,COMPLETED,0,China,"China National Biotec Group Company Limited"
305,NCT04545047,"CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19",2020-05-01,COMPLETED,1,"United States","VA Office of Research and Development"
306,NCT05669677,"Prospective Cohort Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease",2023-03-15,ACTIVENOTRECRUITING,0,"United States","National Institutes of Health Clinical Center (CC)"
307,NCT05089045,"A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above",2021-08-31,COMPLETED,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
308,NCT04381845,"Immunity and COVID Infections in the Psychiatric Population",2021-01-10,RECRUITING,0,France,"Assistance Publique - Hôpitaux de Paris"
309,NCT05195047,"Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 2)",2022-02-27,COMPLETED,0,China,"Peking University"
310,NCT04743947,"Observational Study on the Effects of SARS-CoV-2 Vaccination in Dialysis and Kidney Transplant Patients",2020-12-21,RECRUITING,0,Germany,"Heinrich-Heine University, Duesseldorf"
311,NCT05200754,"A Randomized Open Label Phase-II Clinical Trial With or Without Infusion of Plasma From Subjects After Convalescence of SARS-CoV-2 Infection in High-Risk Patients With Confirmed Severe SARS-CoV-2 Disease",2020-09-03,UNKNOWN,0,Germany,"University Hospital Heidelberg"
312,NCT04964154,"Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study",2021-02-17,UNKNOWN,0,"United States","North Carolina Central University"
313,NCT05463354,"Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines",2022-07-11,COMPLETED,0,Philippines,"WestVac Biopharma Co., Ltd."
314,NCT04958954,"Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity",2021-07-07,COMPLETED,0,"United States","ModernaTX, Inc."
315,NCT05636319,"A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination",2022-11-23,ACTIVENOTRECRUITING,0,"United Arab Emirates,Philippines,Pakistan,Indonesia","Suzhou Abogen Biosciences Co., Ltd."
316,NCT06020118,"Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults",2023-09-25,COMPLETED,0,"United States","Duke University"
317,NCT05112913,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac）Between Different Workshops for Prevention of COVID-19 in Healthy Children Aged 3-17 Years",2021-07-27,ACTIVENOTRECRUITING,0,China,"Sinovac Biotech Co., Ltd"
318,NCT05715918,"Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", of Children at the Age of 12-17 Years Inclusive""",2022-04-01,ACTIVENOTRECRUITING,0,"Russian Federation","Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"
319,NCT05096832,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines",2021-11-03,COMPLETED,0,"Malaysia,Pakistan","Livzon Pharmaceutical Group Inc."
320,NCT05683600,"A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older",2022-12-29,TERMINATED,0,China,"Guangzhou Patronus Biotech Co., Ltd."
321,NCT05197699,"A Multicenter, Prospective Cohort Study to Document the Immunization Status of MS Patients in Germany With Focus on Anti-SARS-CoV-2 Vaccination Response",2021-07-01,TERMINATED,0,Germany,Biogen
322,NCT05364242,"Open-Label Phase 2/3 Clinical Study to Investigate Safety and Immunogenicity of a Single VLA2001 Booster Vaccination in Adult Volunteers, After Receipt of Nationally Rolled Out mRNA COVID-19 Vaccines and/or Natural SARS-CoV-2 Infection",2022-05-09,COMPLETED,0,"Netherlands,New Zealand","Valneva Austria GmbH"
323,NCT05468736,"A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age",2022-07-22,ACTIVENOTRECRUITING,0,"Philippines,Dominican Republic,Honduras,Guatemala,South Africa,United Kingdom,Mexico,Colombia,Spain,United States",Novavax
324,NCT05338736,"Differences in Humoral and Cellular Immunity in First-cycle Vaccinated Patients Infected by SARS-COV-2: an Observational Study",2022-04-01,COMPLETED,0,Italy,"University Magna Graecia"
325,NCT04537949,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults",2020-09-09,COMPLETED,1,Germany,"BioNTech SE"
326,NCT04818736,"COVID Vaccine for Indirect Protection: A Cluster Randomized Controlled Trial in Hutterite Colonies",2021-04-15,WITHDRAWN,0,Canada,"McMaster University"
327,NCT05238649,"A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines",2021-11-10,UNKNOWN,0,China,"Livzon Pharmaceutical Group Inc."
328,NCT05043259,"Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults at 18 Years of Age or Above: a Randomised, Open-label, Parallel-controlled Clinical Trial",2021-09-13,UNKNOWN,0,China,"Jiangsu Province Centers for Disease Control and Prevention"
329,NCT05517642,"Immunogenicity, Efficacy and Safety of Inhaled (IH) Viral Vectored Vaccine (Convidecia, CanSino) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections. A Randomized Observer-blind Controlled Trial.",2022-09-20,COMPLETED,0,Malaysia,"CanSino Biologics Inc."
330,NCT05490342,"Evaluation of SARS-CoV-2 Antibody Response After Vaccination in Liver Transplant Recipients Who Undergo Tailored Immunosuppression Therapy",2022-04-01,COMPLETED,0,Italy,"University of Rome Tor Vergata"
331,NCT05163652,"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on the Basic Immunity of Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above",2021-12-18,UNKNOWN,0,China,ChineseAMS
332,NCT04914832,"Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death",2021-08-30,COMPLETED,0,Swaziland,"University of Witwatersrand, South Africa"
333,NCT05007275,"A Phase I Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers",2021-10-10,ACTIVENOTRECRUITING,0,"United Kingdom","Imperial College London"
334,NCT04437875,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",2020-06-17,COMPLETED,0,"Russian Federation","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
335,NCT04789356,"Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas)",2021-03-18,UNKNOWN,0,Brazil,"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado"
336,NCT05157256,"Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination in a Cohort of Patients With Thalassemic and Falcemic Syndromes",2022-01-01,ACTIVENOTRECRUITING,0,Italy,"Società Italiana Talassemie ed Emoglobinopatie"
337,NCT04527575,"Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)",2020-07-27,COMPLETED,0,"Russian Federation","Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector"""
338,NCT04640233,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects",2020-11-30,UNKNOWN,0,India,"Dr. Reddy's Laboratories Limited"
339,NCT05911087,"A Phase 2/3, Randomized, Double-blinded , Parallel Controlled Trial to Evaluate the Immunogenicity, Safety and Efficacy of A Heterologous Booster Dose With COVID-19 mRNA Vaccines (Bivalent) , in Previously Vaccinated Subjects Against COVID-19 With 2/3 Doses COVID-19 Vaccine Compared to a Booster Dose With mRNA COVID-19 Vaccine（Pfizer Bivalent Vaccine）in Adults.",2023-06-20,NOTYETRECRUITING,0,"","Stemirna Therapeutics"
340,NCT05664932,"Evaluate the Immunogenicity and Safety of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Above Who Have Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine",2022-12-28,ACTIVENOTRECRUITING,0,China,"Guangzhou Patronus Biotech Co., Ltd."
341,NCT05239832,"A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines",2021-08-05,UNKNOWN,0,China,"Livzon Pharmaceutical Group Inc."
342,NCT05260437,"A Phase 1, Open-label, Safety, Reactogenicity, and Immunogenicity Trial of the CV2CoV mRNA Vaccine Against SARS CoV 2 in Seropositive Adult Participants",2022-03-24,COMPLETED,0,"United States",GlaxoSmithKline
343,NCT06167915,"A Randomized, Blinded, Placebo-Controlled, Dose Escalation Phase 1 Trial of Recombinant COVID-19 Trivalent (XBB.1+BQ.1.1+Prototype) Protein Vaccine （CHO Cell）（LYB002V14） in Booster Vaccination in Participants Aged 18 Years Old and Above",2023-12-26,NOTYETRECRUITING,0,China,"Guangzhou Patronus Biotech Co., Ltd."
344,NCT05246137,"A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess the Safety and Immunogenicity of a Booster Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Vaccinated Against COVID-19.",2022-02-03,COMPLETED,0,"Spain,Italy","Hipra Scientific, S.L.U"
345,NCT06391515,"Subacute Thyroiditis in the SARS-CoV-2 Era: a Multicentre Prospective Study",2020-11-23,COMPLETED,0,Italy,"University of Modena and Reggio Emilia"
346,NCT05104385,"Hacettepe Health Cohort: A Prospective Follow-up of the General Health Status and Effectiveness, Durability and Adverse Effects of COVID-19 Vaccine Among Students of Medical and Dental Schools",2021-06-21,COMPLETED,0,Turkey,"Hacettepe University"
347,NCT04841785,"The RECOVAC LESS CoV-2 Study - Long Term Efficacy and Safety of SARS-CoV-2 Vaccination in Patients in Patients With Chronic Kidney Disease Stage G4-G5, on Dialysis or After Kidney Transplantation",2021-04-22,COMPLETED,0,Netherlands,"University Medical Center Groningen"
348,NCT04934215,"Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.",2021-07-28,COMPLETED,0,France,"Fondation Hôpital Saint-Joseph"
349,NCT05109585,"Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination (DANTE-SIRIO 7) Study",2021-04-20,UNKNOWN,0,Poland,"Collegium Medicum w Bydgoszczy"
350,NCT04466085,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years",2020-07-12,UNKNOWN,0,China,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
351,NCT05135585,"Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population",2021-12-01,COMPLETED,0,"New Caledonia","Institut Pasteur"
352,NCT05022407,"Impact of COVID-19 Epidemic on Clinical Outcomes and Service Delivery Among People Living With HIV and Health Care Workers in Mozambique",2021-07-15,COMPLETED,0,Mozambique,"Instituto Nacional de Saúde, Mozambique"
353,NCT05738707,"Clinical Study of SARS-CoV-2 Vaccine Sequentially Enhancing Immune Response in Metabolism-related Fatty Liver Disease Based on Deep Machine Learning",2023-02,NOTYETRECRUITING,0,"","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
354,NCT05181709,"A Phase-1, Open-Label, Placebo-Controlled Evaluation of a Live, Recombinant Newcastle Disease Virus Expressing the Spike Protein of SARS-CoV-2 (NDV-HXP-S), an Investigational Product for Intranasal (IN) and/or Intramuscular (IM) Vaccination in Healthy Adults Previously Immunized Against COVID-19.",2022-02-09,ACTIVENOTRECRUITING,0,"United States","Icahn School of Medicine at Mount Sinai"
355,NCT05094609,"Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 Vector-based Trivalent COVID-19 Vaccines Delivered Via Inhaled Aerosol",2022-01-03,ACTIVENOTRECRUITING,0,Canada,"McMaster University"
356,NCT04521309,"Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients",2020-06-19,COMPLETED,0,Pakistan,"Dow University of Health Sciences"
357,NCT05005156,"A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months.",2021-06-24,UNKNOWN,0,Argentina,"Fundación Huésped"
358,NCT04510207,"Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",2020-07-16,COMPLETED,0,"Jordan,Bahrain,United Arab Emirates,Egypt","China National Biotec Group Company Limited"
359,NCT05132907,"Phase 1, Dose-Escalation Study Of Nanoparticle Carrier-Formulated Self- Replicating Replicon RNA (repRNA) SARS-CoV-2 Vaccine (HDT-301) Targeting A Variant Spike Protein In Unvaccinated Or Previously Vaccinated Healthy Adults",2022-01-24,ACTIVENOTRECRUITING,0,"United States","HDT Bio"
360,NCT04967807,"Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)",2021-08-05,ACTIVENOTRECRUITING,0,Canada,"University Health Network, Toronto"
361,NCT05247307,"Clinical Efficacy of the Infusion of Donor Plasma, Convalescent From SARS-CoV-2 Infection, to Patients With Recent Infection.",2020-03-31,TERMINATED,0,Spain,"Hospital Galdakao-Usansolo"
362,NCT05052307,"Effectiveness of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine on Symptomatic SARS-CoV-2 Infection and COVID-19-related Hospitalizations, Mortality, and Long-term Consequences in Brazil: a Real-world Evidence Study",2021-11-03,COMPLETED,0,Brazil,"Hospital Moinhos de Vento"
363,NCT04470609,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ⩾60 Years",2020-07-10,COMPLETED,0,China,"Institute of Medical Biology, Chinese Academy of Medical Sciences"
364,NCT04348656,"A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)",2020-03-14,TERMINATED,1,"Brazil,United States,Canada","McMaster University"
365,NCT05162456,"Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination in Patients After Organ Transplantation (DANTE-SIRIO 8) Study",2021-07-01,UNKNOWN,0,Poland,"Collegium Medicum w Bydgoszczy"
366,NCT05133609,"COVID-19 VACCINE SAFETY AND EFFECTIVENESS",2021-01-15,UNKNOWN,0,Brazil,"Federal University of Espirito Santo"
367,NCT05774171,"To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2",2023-01-01,RECRUITING,0,China,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
368,NCT04436471,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",2020-06-17,COMPLETED,0,"Russian Federation","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
369,NCT05077254,"A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients",2021-12-06,ACTIVENOTRECRUITING,0,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
370,NCT05067933,"A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally",2021-10-01,COMPLETED,0,"United States",Vaxart
371,NCT05589233,"Clinical Phenotype of Persons Vaccinated Against Sars-CoV-2 Hospitalized for COVID-19 Disease as a Basis for Optimalization of National Vaccination Strategy and Post-exposure Prophylaxis",2021-01-01,COMPLETED,0,Czechia,"University Hospital Hradec Kralove"
372,NCT05430958,"Phase 1 Open Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines",2022-10,WITHDRAWN,0,"","Inovio Pharmaceuticals"
373,NCT04935528,"Study of Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response Between 1 and 3 Months After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center",2021-06-02,COMPLETED,0,France,"Centre Georges Francois Leclerc"
374,NCT04760132,"National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines",2021-02-08,COMPLETED,0,Denmark,"Rigshospitalet, Denmark"
375,NCT05079152,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",2021-05-06,UNKNOWN,0,China,"China National Biotec Group Company Limited"
376,NCT05110911,"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection",2020-04-02,RECRUITING,0,Australia,"University of Melbourne"
377,NCT05042011,"Role of mHealth-based Interventions Including Social Media to Improve Childhood Immunization Coverage During COVID 19 Pandemic in Pakistan: Qualitative Study",2021-03-01,UNKNOWN,0,Pakistan,"Aga Khan University"
378,NCT04870411,"Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics",2021-05-12,TERMINATED,0,France,"Assistance Publique - Hôpitaux de Paris"
379,NCT05124171,"Immunogenicity and Reactogenicity Following a 3rd Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered as a Booster in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination: A Randomized, Single-blinded Multicenter Clinical Trial",2021-12-08,ACTIVENOTRECRUITING,0,France,"Assistance Publique - Hôpitaux de Paris"
380,NCT04902911,"Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)",2021-04-13,TERMINATED,0,"United States","Medical College of Wisconsin"
381,NCT05629793,"Differential Diagnosis of Persistent COVID-19 by Artificial Intelligence",2022-12-14,NOTYETRECRUITING,0,Spain,"Fundacin Biomedica Galicia Sur"
382,NCT04836793,"Study of Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination to Predict Immune Responses in Cancer Patients",2021-04-15,UNKNOWN,0,France,"Centre Hospitalier Universitaire de Besancon"
383,NCT05186571,"Population-based Incidence of Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Danish Children 5-11 Years Old",2021-12-01,UNKNOWN,0,Denmark,"Rigshospitalet, Denmark"
384,NCT05543993,"Serological and Functional Impact of COVID-19 Vaccination on the Maternal Fetal Unit and Infant Immunity",2022-09-29,RECRUITING,0,"United States","Thomas Jefferson University"
385,NCT04962893,"Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)",2021-06-26,COMPLETED,0,Turkey,"The Scientific and Technological Research Council of Turkey"
386,NCT04368728,"A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",2020-04-29,COMPLETED,0,"Argentina,Brazil,Germany,South Africa,Turkey,United States","BioNTech SE"
387,NCT04842305,"Induction of SARS-CoV-2 Spike Glycoprotein Antibodies in Saliva and Plasma in Response to a COVID-19 Infection, Systemic COVID-19 Vaccination, and the Combination of COVID-19 and Vaccination",2021-04,UNKNOWN,0,"","University Hospital Bispebjerg and Frederiksberg"
388,NCT05541861,"An Exploratory Phase I, Randomized, Observer-blind, Active-controlled, Dose-escalation Trial Evaluating the Safety, Tolerability, and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Healthy Adults",2022-11-08,RECRUITING,0,"United States","BioNTech SE"
389,NCT04979871,"Kinetics and Stability of Anti-SARS-CoV-2 Antibodies and Virus Neutralization After COVID-19 Vaccination in a Swiss Cohort",2021-07-22,COMPLETED,0,Switzerland,"University of Zurich"
390,NCT04817371,"Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for SARS-CoV-2 Infection.",2021-03-01,RECRUITING,0,France,"Hopital Foch"
391,NCT04889209,"A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines",2021-05-28,COMPLETED,0,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
392,NCT05057897,"A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19",2022-01-31,TERMINATED,0,"Ukraine,Thailand",AstraZeneca
393,NCT04860297,"A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls",2021-04-16,COMPLETED,1,"United States","ModernaTX, Inc."
394,NCT04757883,"Immunological Follow-up After COVID 19 Vaccination in Kidney Transplant Recipients",2021-02-02,RECRUITING,0,France,"University Hospital, Strasbourg, France"
395,NCT05479383,"Tobacco Use and Uptake of COVID-19 Vaccinations in Finland: a General Population Study",2017-10-02,ACTIVENOTRECRUITING,0,Finland,"Finnish Institute for Health and Welfare"
396,NCT04569383,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19",2020-10-05,COMPLETED,0,Germany,"Universitätsklinikum Hamburg-Eppendorf"
397,NCT05602961,"A Phase I/II Partially Randomized, Active-controlled Observer-blind, Dose-selection, Safety and Immunogenicity Study of GLB-COV2-043, an mRNA Vaccine Candidate Against SARS-CoV-2, Administered as a Single-vaccination Booster to Previously Vaccinated Adults",2023-02-21,WITHDRAWN,0,"","GreenLight Biosciences, Inc."
398,NCT04283461,"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",2020-03-16,COMPLETED,1,"United States","National Institute of Allergy and Infectious Diseases (NIAID)"
399,NCT05710783,"Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2",2022-11-09,COMPLETED,0,Mexico,"Laboratorio Avi-Mex, S.A. de C.V."
400,NCT04845997,"NATIONAL VACCINATION REGISTRY FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC DISEASES OF THE ARGENTINE SOCIETY OF RHEUMATOLOGY",2021-07-01,RECRUITING,0,Argentina,"Sociedad Argentina de Reumatologia"
401,NCT04367883,"Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection",2020-03-01,RECRUITING,0,Spain,"Consorci Sanitari de Terrassa"
402,NCT04864561,"A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (≥12 to <18 Years)",2021-04-26,COMPLETED,0,"United Kingdom","Valneva Austria GmbH"
403,NCT05639998,"Phase 2 Randomized, Multi-centric of Heterologus Prime-Boost Combination of SARS-CoV-2 Vaccines to Evaluate the Immunogenicity and Safety of BBV152 (COVAXIN®) With BBV154 (Adenoviral Intranasal COVID-19 Vaccine) in Healthy Volunteers",2021-09-01,COMPLETED,0,India,"Bharat Biotech International Limited"
404,NCT04942405,"Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial",2021-06-21,COMPLETED,0,Turkey,"Health Institutes of Turkey"
405,NCT05321407,"Vaccine-induced SARS-CoV-2-specific T Cell Responses in Patients With Primary Immune Deficiency Disease",2021-09-24,RECRUITING,0,"United States","Duke University"
406,NCT04801888,"A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years",2021-03-23,COMPLETED,0,China,"Sinovac Biotech Co., Ltd"
407,NCT04918888,"SARS-CoV-2 Vaccination in Oncologic Patients: A Prospective, Explorative Study",2021-04-19,COMPLETED,0,Austria,"Krankenhaus Barmherzige Schwestern Linz"
408,NCT05078905,"Longitudinal Observations of Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases",2021-10-13,RECRUITING,0,"United States","National Institutes of Health Clinical Center (CC)"
409,NCT05379478,"An Evaluation of Immune Responses to SARS-CoV-2 Infection or Vaccination",2020-12-01,RECRUITING,0,"United States","Aditxt, Inc."
410,NCT05343871,"Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy Adults",2022-07-05,COMPLETED,0,"Brazil,Pakistan","Albert B. Sabin Vaccine Institute"
411,NCT05743361,"Studio Sierologico in Volontari Vaccinati Contro COVID-19",2021-01-07,COMPLETED,0,Italy,"Istituto Auxologico Italiano"
412,NCT05597761,"Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)",2023-05-15,RECRUITING,0,Germany,"University of Cologne"
413,NCT05716347,"Safety and Immunogenicity of a Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cell) as Booster Shots in Healthy Adults Aged 18-59 Years Who Have Completed Two Doses of Inactivated SARS-CoV-2 Vaccine",2022-07-13,RECRUITING,0,China,"Binhui Biopharmaceutical Co., Ltd."
414,NCT04872751,"The Malaysian Study On Hemodialysis Patients SARS-COV-2 Vaccination Immune Response: A Prospective Observational Cohort Study",2021-04-27,UNKNOWN,0,Malaysia,"Penang Hospital, Malaysia"
415,NCT05060354,"Immune Response to SARS-CoV2 Vaccinations in Treated MS Patients Compared to Controls",2021-06-01,COMPLETED,0,"United States","Brigham and Women's Hospital"
416,NCT05775887,"A PHASE 1 RANDOMIZED, ACTIVE-CONTROLLED, DOUBLEBLIND, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF AN ADJUVANTED SARS-CoV-2 UQSC2 PROTEIN SUBUNIT VACCINE IN HEALTHY ADULTS, AGED 18 TO 50 YEARS.",2023-05-08,COMPLETED,0,Australia,"The University of Queensland"
417,NCT05321433,"The Association Between Tobacco Use and COVID-19 Infection and Adverse Outcomes in Three Nordic Countries: a Pooled Analysis",2022-04-01,COMPLETED,0,Sweden,"Karolinska Institutet"
418,NCT06162533,"SARS-CoV-2 Re-Infection Risk and Vaccine Efficacy in Austria: SARIVA Study",2023-07-01,COMPLETED,0,Austria,"Medical University of Graz"
419,NCT05074433,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants",2021-10-25,TERMINATED,1,"United States,Mexico","Regeneron Pharmaceuticals"
420,NCT05194033,"Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 1)",2022-03-09,COMPLETED,0,China,"Peking University"
